ME02648B - Jedinjenje pirazin karboksamida - Google Patents

Jedinjenje pirazin karboksamida

Info

Publication number
ME02648B
ME02648B MEP-2017-43A MEP201743A ME02648B ME 02648 B ME02648 B ME 02648B ME P201743 A MEP201743 A ME P201743A ME 02648 B ME02648 B ME 02648B
Authority
ME
Montenegro
Prior art keywords
amino
carboxamide
phenyl
salt
methylpiperazin
Prior art date
Application number
MEP-2017-43A
Other languages
German (de)
English (en)
French (fr)
Inventor
Takahiro Matsuya
Yutaka Kondoh
Itsuro Shimada
Shigetoshi Kikuchi
Kenichi Onda
Hiroki Fukudome
Yukihiro Takemoto
Nobuaki Shindou
Hideki Sakagami
Hisao Hamaguchi
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48799179&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02648(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of ME02648B publication Critical patent/ME02648B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)

Claims (13)

1.Jedinjenje formule (I) ili so istog: (gde R1 predstavlja piperazinil koji je supstituisan sa C1-6 alkilom, piperidinil koji je supstituisan sa C1-6 alkilom, ili piperidinil supstituisan sa piperazinilom koji može biti supstituisan sa C1-6 alkilom, Prsten A predstavlja benzen koji može biti supstituisan sa jednim ili više supstituenata odabranih iz grupe koja se sastoji od halogena, C1-6 alkila koji može biti supstituisan sa jednim ili više atoma halogena, i -O-C1-6 alkila, pirazola koji može biti supstituisan sa C1-6 alkilom, imidazola koji može biti supstituisan sa C1-6 alkilom ili pirimidinom koji može biti supstituisan sa C1-6 alkilom, L1 predstavlja NH-, R2 predstavlja H ili C1-6 alkil, L2 predstavlja -O- ili vezu, Y predstavlja Prsten X, Prsten X predstavlja aromatični heterocikl, nearomatični heterocikl, cikloalkan, ili benzen koji može biti supstituisan sa jednim ili više supstituenata izabranih iz grupe koja se sastoji od halogena, -O- C1-6 alkila, -CN, cikloalkila, arila, aromatične heterociklične grupe, ne-aromatične heterociklične grupe koja može biti supstituisana sa C1-6 alkil, okso, i C1-6 alkilom koji može biti supstituisan sa jednim ili više atoma halogena, L3 predstavlja -NH-, -N(C1-6 alkil)- ili vezu, M predstavlja -C(O), R3 predstavlja H, R4 predstavlja H.)
2. Jedinjenje ili so istog prema patentnom zahtevu 1, gde je L2 -O-, Prsten X je benzen koji može biti supstituisan sa C1-6 alkilom, i L3 je -NH-.
3. Jedinjenje ili so istog prema patentnom zahtevu 1, gde je L2 -O-, Prsten X je nearomatični heterocikl, i L3 je veza.
4. Jedinjenje ili so istog prema patentnom zahtevu 1, gde je L2 veza, Prsten X je nearomatični heterocikl, a L3 je veza.
5. Jedinjenje ili so istog prema patentnom zahtevu 3, gde je Prsten X pirolidin ili piperidin.
6. Jedinjenje ili so istog prema patentnom zahtevu 4, gde je Prsten X piperidin ili tetrahidropiridin.
7. Jedinjenje ili so istog prema patentnom zahtevu 1, koje je 5-[3-(akriloilamino)fenoksi]-6-etil-3-{[4-(4-metilpiperazin-1-il)fenil]amino}pirazin-2-karboksamid, 5-[3-(akriloilamino)-2-metilfenoksi]-6-etil-3-{[4-(4-metilpiperazin-1-il)fenil]amino} pirazin-2-karboksamid, 5-[3-(akriloilamino)fenoksi]-6-izopropil-3-{[4-(4-metilpiperazin-1-il)fenil]amino} pirazin-2-karboksamid, 5-(1-akriloilpiperidin-4-il)-6-etil-3-({3-metil-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]fenil}amino)pirazin-2-karboksamid, 5-[3-(akriloilamino)fenoksi]-3-{[4-(4-metilpiperazin-1-il)fenil]amino}pirazin-2-karboksamid, 5-[3-(akriloilamino)fenoksi]-6-etil-3-{[4-metoksi-3-(4-metilpiperazin-1-il)fenil] amino}pirazin-2-karboksamid, 5-[3-(akriloilamino)fenoksi]-6-etil-3-{[4-(4-etilpiperazin-1-il)fenil]amino}pirazin-2-karboksamid, 5-{[(3R)-1-akriloilpirolidin-3-il]oksi}-6-etil-3-({4-[4-(4-metilpiperazin-1-il)piperidin-1-il]fenil}amino)pirazin-2-karboksamid, 5-[3-(akriloilamino)fenoksi]-6-izopropil-3-{[1-(1-metilpiperidin-4-il)-1H-pirazol-4-il]amino}pirazin-2-karboksamid, 5-[3-(akriloilamino)fenoksi]-3-({4-[(3S)-3,4-dimetilpiperazin-1-il]fenil}amino)-6-etilpirazin-2-karboksamid, 5-[3-(akriloilamino)fenoksi]-3-({4-[(3R)-3,4-dimetilpiperazin-1-il]fenil}amino)-6-etilpirazin-2-karboksamid, 5-(1-akriloilpiperidin-4-il)-6-etil-3-({4-[4-(4-metilpiperazin-1-il)piperidin-1-il]fenil} amino)pirazin-2-karboksamid, 5-{[(3R)-1-akriloilpirolidin-3-il]oksi}-6-etil-3-{[4-(4-metilpiperazin-1-il)fenil] amino}pirazine-2-karboksamid, 5-{[(3R)-1-akriloilpiperidin-3-il]oksi}-6-etil-3-({4-[4-(4-metilpiperazin-1-il)piperidin-1-il]fenil}amino)pirazin-2-karboksamid, 5-{[(3R)-1-akriloilpiperidin-3-il]oksi}-6-etil-3-({3-metil-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]fenil}amino)pirazin-2-karboksamid, ili 5-[5-(akriloilamino)-2-fluorofenoksi]-6-etil-3-{[4-(4-metilpiperazin-1-il)fenil]amino} pirazin-2-karboksamid, ili so istog.
8. Farmaceutska kompozicija koja sadrži jedinjenje ili so istog prema patentnom zahtevu 7, i farmaceutski prihvatljiv ekscipijens.
9. Primena jedinjenja ili soli istog prema patentnom zahtevu 7, za proizvodnju farmaceutske kompozicije za prevenciju i/ili lečenje kancera pozitivnog na EGFR T790M mutaciju.
10. Jedinjenje ili so istog prema patentnom zahtevu 7 za primenu u lečenju kancera pozitivnog na EGFR T790M mutaciju.
11. Jedinjenje ili so istog prema patentnom zahtevu 7, koje je 5-[3-(akriloilamino)fenoksi]-6-izopropil-3-{[4-(4-metilpiperazin-1-il)fenil]amino}pirazin-2-karboksamid ili so istog.
12. Jedinjenje ili so istog prema patentnom zahtevu 7, koje je 5-(1-akriloilpiperidin-4-il)-6-etil-3-({3-metil-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]fenil}amino)pirazin-2-karboksamid ili so istog.
13. Jedinjenje ili so istog prema patentnom zahtevu 7, koje je 5-{[(3R)-1-akriloilpirolidin-3-il]oksi}-6-etil-3-({4-[4-(4-metilpiperazin-1-il)piperidin-1-il]fenil} amino)pirazin-2-karboksamid ili so istog.
MEP-2017-43A 2012-01-17 2013-01-15 Jedinjenje pirazin karboksamida ME02648B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012007525 2012-01-17
EP13738947.4A EP2805940B1 (en) 2012-01-17 2013-01-15 Pyrazine carboxamide compound
PCT/JP2013/050579 WO2013108754A1 (ja) 2012-01-17 2013-01-15 ピラジンカルボキサミド化合物

Publications (1)

Publication Number Publication Date
ME02648B true ME02648B (me) 2017-06-20

Family

ID=48799179

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2017-43A ME02648B (me) 2012-01-17 2013-01-15 Jedinjenje pirazin karboksamida

Country Status (29)

Country Link
US (1) US9085540B2 (me)
EP (1) EP2805940B1 (me)
JP (1) JP5532366B2 (me)
KR (1) KR101985050B1 (me)
CN (1) CN104080774B (me)
AR (1) AR089727A1 (me)
AU (1) AU2013210438B2 (me)
BR (1) BR112014017466A8 (me)
CA (1) CA2860765C (me)
CY (1) CY1118644T1 (me)
DK (1) DK2805940T3 (me)
EA (1) EA026353B1 (me)
ES (1) ES2613399T3 (me)
HR (1) HRP20170226T1 (me)
HU (1) HUE033177T2 (me)
IL (1) IL233437A (me)
LT (1) LT2805940T (me)
ME (1) ME02648B (me)
MX (1) MX355434B (me)
PH (1) PH12014501456A1 (me)
PL (1) PL2805940T3 (me)
PT (1) PT2805940T (me)
RS (1) RS55704B1 (me)
SI (1) SI2805940T1 (me)
SM (2) SMT201700094T1 (me)
TW (1) TWI532727B (me)
UA (1) UA111010C2 (me)
WO (1) WO2013108754A1 (me)
ZA (1) ZA201405045B (me)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9598398B2 (en) 2013-04-04 2017-03-21 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3060550B1 (en) * 2013-10-21 2019-05-15 Merck Patent GmbH Heteroaryl compounds as btk inhibitors and uses thereof
RU2646758C2 (ru) * 2013-12-05 2018-03-07 Ф. Хоффманн-Ля Рош Аг Гетероарил пиридоны и азапиридоны с электрофильной функциональностью
KR20160093675A (ko) * 2013-12-05 2016-08-08 파마싸이클릭스 엘엘씨 브루톤 티로신 키나제의 억제제
TW201622744A (zh) 2014-03-04 2016-07-01 美國禮來大藥廠 癌症之組合療法
CN106456636A (zh) * 2014-05-28 2017-02-22 安斯泰来制药株式会社 包含吡嗪甲酰胺化合物作为活性成分的药物组合物
CN105085489B (zh) 2014-11-05 2019-03-01 益方生物科技（上海）有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
JPWO2016121777A1 (ja) * 2015-01-28 2017-11-02 アステラス製薬株式会社 ピラジンカルボキサミド化合物の製造方法及びその合成中間体
HK1250491A1 (zh) * 2015-04-27 2018-12-21 安斯泰来制药有限公司 稳定化的医药组合物
JP2018104290A (ja) * 2015-04-28 2018-07-05 アステラス製薬株式会社 ピラジンカルボキサミド化合物を有効成分とする医薬組成物
RU2017145650A (ru) * 2015-06-02 2019-07-15 Фармасайкликс Элэлси Ингибиторы тирозинкиназы брутона
US10308660B2 (en) * 2015-06-19 2019-06-04 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
JP2019014653A (ja) * 2015-11-27 2019-01-31 アステラス製薬株式会社 がん免疫を介したがん治療方法
MY196809A (en) 2015-12-24 2023-05-03 Kyowa Kirin Co Ltd (),()-unsaturated amide compound
WO2017176565A1 (en) 2016-04-07 2017-10-12 Eli Lilly And Company Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
PE20190624A1 (es) * 2016-07-12 2019-04-26 Revolution Medicines Inc 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostericos de shp2
US20190282569A1 (en) * 2016-10-26 2019-09-19 Astellas Pharma Inc. Stable pharmaceutical composition
CN108419436B (zh) * 2016-12-09 2021-05-04 深圳市塔吉瑞生物医药有限公司 一种取代的吡嗪甲酰胺类化合物及包含该化合物的组合物及其用途
US11447471B2 (en) * 2017-06-23 2022-09-20 Kyowa Kirin Co., Ltd. α,β-unsaturated amide compound
TWI798334B (zh) * 2018-01-31 2023-04-11 大陸商迪哲（江蘇）醫藥股份有限公司 Ｅｒｂｂ／ｂｔｋ抑制劑
WO2020063856A1 (zh) * 2018-09-30 2020-04-02 南京明德新药研发有限公司 作为flt3和axl抑制剂的3,9-二氮杂螺[5,5]十一烷类化合物
CN112062728A (zh) * 2019-05-25 2020-12-11 上海鑫凯化学科技有限公司 一种3,5-二氯-6-乙基吡嗪甲酰胺的合成方法
WO2021097110A1 (en) * 2019-11-13 2021-05-20 Genentech, Inc. Therapeutic compounds and methods of use
CN111266090B (zh) * 2020-02-19 2022-11-15 渤海大学 一种快速吸附和选择性分离阳离子染料污染物的吸附分离材料及其应用
EP4159731A4 (en) * 2020-06-01 2024-06-26 Wigen Biomedicine Technology (Shanghai) Co., Ltd. New pyrazine compound
CN113943288A (zh) * 2020-07-17 2022-01-18 微境生物医药科技(上海)有限公司 5,6-二氢吡嗪并[2,3-c]异喹啉化合物
TW202220975A (zh) * 2020-09-30 2022-06-01 英屬開曼群島商百濟神州有限公司 作為ｈｐｋ１抑制劑之３－［（１ｈ－吡唑－４－基）氧基］吡－２－胺化合物及其用途
JP2024509625A (ja) 2021-03-15 2024-03-04 ノバルティス アーゲー ベンゾイソオキサゾール誘導体及びその使用
AU2022426699A1 (en) 2021-12-30 2024-07-11 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
DE10063435A1 (de) 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
CA2537978C (en) 2003-09-15 2011-08-02 Wyeth Substituted quinolines as protein tyrosine kinase enzyme inhibitors
RS52119B (sr) 2004-05-06 2012-08-31 Warner-Lambert Company Llc 4-fenilamino-hinazolin-6-il-amidi
WO2008117050A1 (en) 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
TWI377944B (en) 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
TWI475996B (zh) 2007-10-19 2015-03-11 Celgene Avilomics Res Inc 雜芳基化合物及其用途
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
CA2723205C (en) * 2008-04-16 2017-03-14 Portola Pharmaceuticals, Inc. 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinase inhibitors
KR20100132550A (ko) * 2008-04-16 2010-12-17 포톨라 파마슈티컬스, 인코포레이티드 ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8450335B2 (en) 2008-06-27 2013-05-28 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
JP5918693B2 (ja) 2009-05-05 2016-05-18 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Ｅｇｆｒ阻害剤及び疾患の治療方法
KR101614572B1 (ko) 2009-05-08 2016-04-21 아스테라스 세이야쿠 가부시키가이샤 디아미노 헤테로환 카르복사미드 화합물
WO2011140338A1 (en) 2010-05-05 2011-11-10 Gatekeeper Pharmaceuticals, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith

Also Published As

Publication number Publication date
IL233437A (en) 2017-01-31
MX2014008647A (es) 2014-11-25
BR112014017466A2 (pt) 2017-06-13
EA201491371A1 (ru) 2014-11-28
SMT201700094T1 (it) 2017-03-08
HRP20170226T1 (hr) 2017-04-07
PT2805940T (pt) 2017-02-03
SI2805940T1 (sl) 2017-04-26
CN104080774A (zh) 2014-10-01
US20140323463A1 (en) 2014-10-30
IL233437A0 (en) 2014-08-31
CA2860765C (en) 2018-06-26
EP2805940B1 (en) 2016-11-23
CY1118644T1 (el) 2017-07-12
PL2805940T3 (pl) 2017-06-30
ES2613399T3 (es) 2017-05-24
UA111010C2 (uk) 2016-03-10
PH12014501456A1 (en) 2014-10-08
CN104080774B (zh) 2017-02-22
EP2805940A4 (en) 2015-04-15
JPWO2013108754A1 (ja) 2015-05-11
KR20140114404A (ko) 2014-09-26
KR101985050B1 (ko) 2019-05-31
MX355434B (es) 2018-04-18
BR112014017466A8 (pt) 2017-07-04
RS55704B1 (sr) 2017-07-31
US9085540B2 (en) 2015-07-21
AR089727A1 (es) 2014-09-10
CA2860765A1 (en) 2013-07-25
TW201341373A (zh) 2013-10-16
AU2013210438A1 (en) 2014-07-17
AU2013210438B2 (en) 2016-11-10
EP2805940A1 (en) 2014-11-26
HUE033177T2 (en) 2017-11-28
DK2805940T3 (en) 2017-02-06
JP5532366B2 (ja) 2014-06-25
ZA201405045B (en) 2016-01-27
SMT201700094B (it) 2017-03-08
TWI532727B (zh) 2016-05-11
WO2013108754A1 (ja) 2013-07-25
LT2805940T (lt) 2017-01-10
EA026353B1 (ru) 2017-03-31
HK1203491A1 (en) 2015-10-30

Similar Documents

Publication Publication Date Title
ME02648B (me) Jedinjenje pirazin karboksamida
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
NZ588652A (en) Carboxamide compounds for the treatment of metabolic disorders
NZ592297A (en) 2-Aryl-5-heteroaryl pyridine and pyrimidine derivatives as pharmaceutical active agents
RU2019132254A (ru) Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
HRP20151435T1 (hr) Diamino heterociklički karboksamidni spoj
JP2013517283A5 (me)
MX373178B (es) Fungicidas de benceno sustituido.
CA2585053A1 (en) Substituted n-acyl (hetero)aryl compounds as c-fms kinase inhibitors
NO20084832L (no) Pyrimidinderivater som P13K-inhibitorer
NZ597528A (en) Inhibitors of flaviviridae viruses
RU2010138577A (ru) ИНГИБИТОРЫ РЕЦЕПТОРА ХЕМОКИНА CxCR3
AR104963A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
NZ600816A (en) Inhibitors of flaviviridae viruses
UA111725C2 (uk) Кристалічний (r)-(e)-2-(4-(2-(5-(1-(3,5-дихлорпіридин-4-іл)етоксі)-1h-індазол-3-іл)вініл)-1h-піразол-1-іл)етанол
PE20091002A1 (es) Analogos dipeptidos como inhibidores del factor de coagulacion
AR092045A1 (es) Combinaciones farmaceuticas
JP2010508338A5 (me)
ME02200B (me) Postupci za korisćenje alk inhibitora
HRP20141199T1 (hr) Kombinacija od spoja glyt1 s antipsihoticima
NZ620635A (en) Compounds for binding to the platelet specific glycoprotein iib/iiia and their use for imaging of thrombi
HRP20140252T1 (hr) Derivati imidazola kao inhibitori kazeinske kinaze
NZ630488A (en) Piperidine derivatives for gpr119 agonist
HRP20221454T1 (hr) Piridinamin-piridonski i pirimidinamin-piridonski spojevi
NO20085052L (no) 4-((fluorofenoksyl)fenylmetyl)piperidin metansulfonat: anvendelser, synteseprosess og farmasoytiske sammensetninger